Q4 2024 Ambu A/S Earnings Call Transcript
Key Points
- Ambu AS (AMBFF) reported a 10.6% revenue growth in Q4, with a full-year growth of 13.8%, driven primarily by a 19.7% increase in endoscopy.
- The company achieved an EBIT margin of 10.6% and a positive cash flow of DKK98 million for the full year.
- Ambu AS (AMBFF) received FDA clearance for its Ascope five, Cyto HD, enhancing its product offerings in neurology.
- The company completed the transition to bioplastic handles for all endoscopes, aligning with sustainability goals.
- Ambu AS (AMBFF) is optimistic about future growth in pulmonology, supported by a comprehensive product portfolio and new product launches like the video laryngoscope.
- Despite strong performance, Ambu AS (AMBFF) faces potential revenue loss due to losing exclusivity on some contracts.
- The company reported a 5.7% growth in pulmonology for the quarter, impacted by high comparables from large orders in the previous year.
- Ambu AS (AMBFF) booked a total impairment of DKK334 million related to its GI segment, reflecting longer-than-expected market penetration times.
- The guidance for EBIT margin remains wide, indicating uncertainty in achieving significant margin improvements.
- The company anticipates potential volume losses in anesthesia and patient monitoring due to price increases, which could impact future growth.
/-
Hello everyone and welcome to this call where we from Amber will present our Q4 and full year results from our fiscal year 2,324.
The agenda for today is that we will first present our results on the business and the financials and then we will hand over to the operator to moderate the Q&A session.
I'm Breg Milian and I'm the CEO of Ambu. And with me today, I have Henrik Sbender, our CFO.
So let's dive into the results from our Q4 and the full year in Q4, we delivered 10.6% revenue growth split into 4.5% growth in organic revenue growth in endoscopy and 4.3% in anesthesia and patient monitoring.
In terms of profitability, we had an ebit margin also amounting to 10.6%. And then we had a positive cash flow of DKK98 million for the full year. This means that in terms of revenue growth, we delivered 13.8% and this was mainly driven by endoscopy where we grew 19.7%.
So this strong performance comes after a year where we have had a lot of momentum in the business at Ambu. And where I'm grateful for the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
